Influencing factors of low vision 2 years after vitrectomy for proliferative diabetic retinopathy: an observational study.
Anti-VEGF
Low vision
Pars plana vitrectomy
Proliferative diabetic retinopathy
Surgical complication
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
10 Jul 2023
10 Jul 2023
Historique:
received:
09
03
2023
accepted:
05
07
2023
medline:
12
7
2023
pubmed:
11
7
2023
entrez:
10
7
2023
Statut:
epublish
Résumé
Proliferative diabetic retinopathy (PDR) can seriously affect the vision and quality of life of patients. The present study aimed to evaluate the clinical effect of vitrectomy for PDR by observing visual recovery and postoperative complications and to explore the factors influencing low vision. This was a case series observational study. Consecutive eyes of patients with PDR who underwent 23G vitrectomy in our hospital within one year (2019.11-2020.11) were collected and followed up for more than 2 years. Patients' visual acuity, surgical complications and management were collected before the operation and during the follow-up. Decimal visual acuity was recorded and converted to the logarithm of the minimal angle of resolution (logMAR) for statistical analysis. Excel was used to establish a database, and SPSS 22.0 statistical software was used for data analysis. A total of 127 patients and 174 eyes were included in the study. The mean age was 57.8 years. The best corrected visual acuity (BCVA) was < 0.3 in 89.7% of eyes before surgery and ≥ 0.3 in 48.3% of eyes after surgery. Among 174 eyes, visual acuity improved in 83.3%. There was no change in 8.6% of eyes, while 8.1% of eyes had decreased visual acuity after surgery. The average logMAR visual acuity was 1.5 ± 0.7 before surgery and 0.7 ± 0.6 after surgery, indicating significant improvement (p < 0.05). Logistic regression analysis showed that intraoperative silicone oil filling and postoperative complication were significant risk factors for postoperative low vision, while preoperative pseudophakic lens and postoperative intra vitreal injection of anti-VEGF were protective factors for vision recovery (p < 0.05). The incidence of postoperative complications was 15.5%, top three of which were vitreous haemorrhage, neovascular glaucoma and traction retinal detachment. Vitrectomy is safe and effective in the treatment of PDR with few complication. Postoperative intra vitreal injection of anti-VEGF is a protective factor for vision recovery. The trial registration number is ChiCRT2100051628, and the date of registration was September 28, 2021.
Sections du résumé
BACKGROUND
BACKGROUND
Proliferative diabetic retinopathy (PDR) can seriously affect the vision and quality of life of patients. The present study aimed to evaluate the clinical effect of vitrectomy for PDR by observing visual recovery and postoperative complications and to explore the factors influencing low vision.
METHODS
METHODS
This was a case series observational study. Consecutive eyes of patients with PDR who underwent 23G vitrectomy in our hospital within one year (2019.11-2020.11) were collected and followed up for more than 2 years. Patients' visual acuity, surgical complications and management were collected before the operation and during the follow-up. Decimal visual acuity was recorded and converted to the logarithm of the minimal angle of resolution (logMAR) for statistical analysis. Excel was used to establish a database, and SPSS 22.0 statistical software was used for data analysis.
RESULTS
RESULTS
A total of 127 patients and 174 eyes were included in the study. The mean age was 57.8 years. The best corrected visual acuity (BCVA) was < 0.3 in 89.7% of eyes before surgery and ≥ 0.3 in 48.3% of eyes after surgery. Among 174 eyes, visual acuity improved in 83.3%. There was no change in 8.6% of eyes, while 8.1% of eyes had decreased visual acuity after surgery. The average logMAR visual acuity was 1.5 ± 0.7 before surgery and 0.7 ± 0.6 after surgery, indicating significant improvement (p < 0.05). Logistic regression analysis showed that intraoperative silicone oil filling and postoperative complication were significant risk factors for postoperative low vision, while preoperative pseudophakic lens and postoperative intra vitreal injection of anti-VEGF were protective factors for vision recovery (p < 0.05). The incidence of postoperative complications was 15.5%, top three of which were vitreous haemorrhage, neovascular glaucoma and traction retinal detachment.
CONCLUSION
CONCLUSIONS
Vitrectomy is safe and effective in the treatment of PDR with few complication. Postoperative intra vitreal injection of anti-VEGF is a protective factor for vision recovery.
TRIAL REGISTRATION
BACKGROUND
The trial registration number is ChiCRT2100051628, and the date of registration was September 28, 2021.
Identifiants
pubmed: 37430223
doi: 10.1186/s12886-023-03071-4
pii: 10.1186/s12886-023-03071-4
pmc: PMC10331988
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
309Subventions
Organisme : Natural Science Foundation of Shandong Province
ID : ZR2019PH065
Organisme : Natural Science Foundation of Shandong Province
ID : ZR2019PH065
Organisme : Science and Technology Innovation and Development Project of Taian city
ID : 2020NS105
Organisme : Science and Technology Innovation and Development Project of Taian city
ID : 2020NS105
Organisme : Science and Technology Innovation and Development Project of Taian city
ID : 2020NS105
Organisme : Medical Science and Technology Development Program of Shandong Province
ID : 2018WS140
Organisme : Medical Science and Technology Development Program of Shandong Province
ID : 2018WS140
Informations de copyright
© 2023. The Author(s).
Références
Invest Ophthalmol Vis Sci. 2012 Sep 21;53(10):6403-10
pubmed: 22899753
J Glaucoma. 2013 Sep;22(7):572-6
pubmed: 22407392
Acta Ophthalmol. 2021 Feb;99(1):83-89
pubmed: 32643273
JAMA. 2015 Nov 24;314(20):2137-2146
pubmed: 26565927
Eye (Lond). 2022 Mar;36(3):619-626
pubmed: 33824510
Eur J Ophthalmol. 2007 Nov-Dec;17(6):954-60
pubmed: 18050123
Ophthalmology. 2001 Oct;108(10):1751-6
pubmed: 11581045
Acta Ophthalmol. 2016 Jun;94(4):414-5
pubmed: 27010230
JAMA Ophthalmol. 2018 Oct 1;136(10):1138-1148
pubmed: 30043039
Am J Ophthalmol. 2021 Mar;223:267-274
pubmed: 33096065
Lancet. 2017 Jun 3;389(10085):2193-2203
pubmed: 28494920
Int J Ophthalmol. 2019 Feb 18;12(2):302-311
pubmed: 30809489
PLoS One. 2021 Jan 14;16(1):e0244281
pubmed: 33444332
Br J Ophthalmol. 2018 Aug;102(8):1077-1085
pubmed: 29246890
Int Ophthalmol. 2020 Sep;40(9):2413-2422
pubmed: 32405956
Retina. 2015 Oct;35(10):1931-42
pubmed: 26398553
Acta Ophthalmol. 2022 Jun;100(4):e864-e880
pubmed: 34846097
BMJ. 2020 Apr 28;369:m997
pubmed: 32345662
BMC Ophthalmol. 2022 Jan 5;22(1):11
pubmed: 34983449
Ophthalmology. 2011 Nov;118(11):2218-26
pubmed: 21724263
Dev Ophthalmol. 2014;54:196-203
pubmed: 25196770